Multiple Sclerosis Nervous System Diseases
Conditions
Interventions
We plan to follow up a cohort of patients with Multiple Sclerosis (MS), clinically isolated syndrome (CIS), and healthy controls for a little over a decade after their initial assessments, n=140 out o
Sponsors
University College London
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Included in the original research study (ref: 917/09). 2. Aged 18-65 years (at time of original study) 3. Able to undertake written informed consent in English 4. Diagnosis of clinically definite MS or were healthy controls with no known neurological disease
Exclusion criteria
Exclusion criteria: 1. Involvement in other research studies or medical interventions which might have contraindications for this study 2. Neurological disease other than CIS and MS that impedes study interpretation 3. Contraindication to MRI scanning is not an exclusion criteria for the study, however participants must meet safety criteria to take part in this element of the study. Participants will be asked to complete the NMR Research Unit’s MRI safety checklist to determine whether or not it is safe to proceed with MRI scanning.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Cortical grey matter atrophy measured using 3D T1-weighted volumetric MRI scans at the single study visit 2. Transition to secondary progressive MS measured using clinical assessment based on history and examination at the single study visit 3. Disability accrual measured using the Expanded Disability Status Scale (EDSS), Multiple Sclerosis Functional Composite (MSFC), and cognitive measures at the single study visit | — |
Secondary
| Measure | Time frame |
|---|---|
| There are no secondary outcome measures | — |
Countries
United Kingdom
Outcome results
None listed